Nervgen Pharma Corp Stock Performance
| NGENF Stock | USD 1.85 0.06 3.35% |
The company secures a Beta (Market Risk) of 0.73, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NervGen Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NervGen Pharma is expected to be smaller as well. At this point, NervGen Pharma Corp has a negative expected return of -0.0186%. Please make sure to verify NervGen Pharma's kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if NervGen Pharma Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days NervGen Pharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, NervGen Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 5.6 M | |
| Total Cashflows From Investing Activities | -45.1 K |
NervGen |
NervGen Pharma Relative Risk vs. Return Landscape
If you would invest 201.00 in NervGen Pharma Corp on August 25, 2024 and sell it today you would lose (16.00) from holding NervGen Pharma Corp or give up 7.96% of portfolio value over 90 days. NervGen Pharma Corp is currently producing negative expected returns and takes up 4.6991% volatility of returns over 90 trading days. Put another way, 41% of traded otc stocks are less volatile than NervGen, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NervGen Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NervGen Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as NervGen Pharma Corp, and traders can use it to determine the average amount a NervGen Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.004
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NGENF |
Estimated Market Risk
| 4.7 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NervGen Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NervGen Pharma by adding NervGen Pharma to a well-diversified portfolio.
NervGen Pharma Fundamentals Growth
NervGen OTC Stock prices reflect investors' perceptions of the future prospects and financial health of NervGen Pharma, and NervGen Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NervGen OTC Stock performance.
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Total Asset | 17.9 M | |||
About NervGen Pharma Performance
By analyzing NervGen Pharma's fundamental ratios, stakeholders can gain valuable insights into NervGen Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NervGen Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NervGen Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about NervGen Pharma Corp performance evaluation
Checking the ongoing alerts about NervGen Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for NervGen Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NervGen Pharma Corp generated a negative expected return over the last 90 days | |
| NervGen Pharma Corp may become a speculative penny stock | |
| NervGen Pharma Corp has high historical volatility and very poor performance | |
| NervGen Pharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NervGen Pharma Corp has accumulated about 11.65 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2. | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing NervGen Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NervGen Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NervGen Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NervGen Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NervGen Pharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of NervGen Pharma's otc stock. These opinions can provide insight into NervGen Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NervGen OTC Stock analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |